Early-Stage Breast Cancer: Long-Term Validation of Genomic Testing

Dr. Allison DiPasquale asks Dr. Sonya Reid how longer-term follow-up from landmark studies has influenced confidence in the use of genomic assays for early-stage HR-positive, HER2-negative breast cancer. Dr. Reid explains that extended follow-up data from trials such as TAILORx have reinforced the long-term prognostic and predictive value of genomic testing, particularly given the potential for late recurrence in hormone receptor-positive disease. She notes that the consistency between the initial trial findings and subsequent long-term outcomes has strengthened clinician confidence in incorporating genomic assays into routine practice. The discussion highlights that these data continue to support the safe omission of adjuvant chemotherapy for appropriately selected patients with lower recurrence scores while maintaining favorable long-term outcomes. Together, the faculty emphasize that ongoing validation of genomic assays has provided reassurance that evidence-based, individualized treatment decisions in early-stage breast cancer remain durable over time and continue to support precision medicine approaches in clinical practice.